 Pyrimidinones
"Pyrimidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D011744
|
| MeSH Number(s) |
D03.383.742.698
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrimidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrimidinones".
This graph shows the total number of publications written about "Pyrimidinones" by people in UAMS Profiles by year, and whether "Pyrimidinones" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2025 | 0 | 1 | 1 | | 2024 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 | | 2020 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2011 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pyrimidinones" by people in Profiles over the past ten years.
-
Lee EQ, Alexander BM, Romo CG, Supko JG, Agar NYR, Talebi Z, Ahluwalia MS, Desai AS, Dietrich J, Kaley TJ, Peereboom DM, Gantchev J, Baquer G, Santagata S, Takebe N, Desideri S, Fisher JD, Sims M, Ye X, Ligon KL, Nabors LB, Grossman SA, Wen PY. Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. Clin Cancer Res. 2025 Mar 17; 31(6):983-992.
-
Han S, Tushoski-Alem?n GW, Zhang P, Zheng G, Zhou D, Huo Z, Licht J, George TJ, Allegra C, Trevino JG, Hughes SJ. A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. Neoplasia. 2025 Jan; 59:101070.
-
Cournoyer E, Ferrell J, Sharp S, Ray A, Jordan M, Dandoy C, Grimley M, Roy S, Lorsbach R, Merrow AC, Nelson A, Bartlett A, Picarsic J, Kumar A. Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders. Haematologica. 2024 04 01; 109(4):1137-1148.
-
Bauer TM, Moore KN, Rader JS, Simpkins F, Mita AC, Beck JT, Hart L, Chu Q, Oza A, Tinker AV, Imedio ER, Kumar S, Mugundu G, Jenkins S, Chmielecki J, Jones S, Spigel D, Fu S. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol. 2023 Jul; 18(4):517-530.
-
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
-
Fang B, Kannan A, Guo T, Gao L. Simultaneously targeting DNA damage repair pathway and mTORC1/2 results in small cell lung cancer growth arrest via ER stress-induced apoptosis. Int J Biol Sci. 2018; 14(10):1221-1231.
-
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, Golitz BT, He X, Santos C, Darr DB, Gallagher K, Graves LM, Perou CM, Carey LA, Earp HS, Johnson GL. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discov. 2017 03; 7(3):302-321.
-
Smith JA, Mayeux PR, Schnellmann RG. Delayed Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Inhibition by Trametinib Attenuates Systemic Inflammatory Responses and Multiple Organ Injury in Murine Sepsis. Crit Care Med. 2016 08; 44(8):e711-20.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|